A company is moving forward on a $100 million expansion of its pharmaceutical manufacturing operations in southern Indiana.

The state of Indiana and the city of Bloomington announced Monday that Somerset, New Jersey-based Catalent Inc. plans a "significant expansion" of its manufacturing of biologics, which are drugs made from living cells instead of chemicals. The expansion in Bloomington includes creating up to 200 new jobs by the end of 2024.

The maker of drug delivery technologies is working to expand drug substance manufacturing capacity and other capacity due to projected growth.

Bloomington Director of Communications Yael Ksander says the expansion is part of a long history of growth of science and technology in Bloomington.

“We have gotten positioned over the past five and a half decades as a fairly formidable hub for the life sciences and the biosciences,” she says.

Catalent purchased Cook Pharmica in 2017 for $950 million. The company already employs about 900 people in Bloomington.

The Indiana Economic Development Corp. has offered Catalent up to $2.4 million in conditional tax credits based on the company's job creation plans. The city of Bloomington is considering additional incentives.

Ksander says that could include tax abatements, which would be phased in over ten years. That proposal must be approved by the Bloomington Economic Development Commission and the city council before it can be enacted.

Taylor Haggerty contributed to this report. This post has been updated.